Key facts
- Acelot’s last known valuation is $48.2M (Jul 2025).
- It has raised $24.2M across 1 recorded rounds; the latest was Early Stage VC ($8.7M) in Nov 2024.
- Notable investors include US National Science Foundation, University of California, California Life Sciences, Santa Barbara, U.S. Department of Health and Human Services.
- Acelot has filed 3 Form Ds with the SEC since 2024, most recently Jul 2025 ($8.7M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Acelot
Funding rounds
1 roundsAbout Acelot
Operator of a biopharmaceutical company intended for drug discovery. The company's joint pharmacophore space (jps) technology utilizes a 3D pharmacophore analysis method to predict drug-relevant properties with accuracy and develops target therapies with a high degree of therapeutic predictability, enabling physicians to discover novel treatments for Alzheimer's Disease and central nervous system disorders.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2006
- Employees
- 14
- Website
- acelot.com/
- Ownership
- Privately Held (backing)
Acelot doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Acelot shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Acelot in its N-PORT filings yet. We sweep new filings monthly.